Publications

18-Sep-2023	Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection

26-May-2023	A phase I/II trial of NOX66 in combination with nivolumab in patients with advanced cancer

15-Nov-2022	CRO-67 is a Novel Therapeutic for Pancreatic Cancer: Implications for Tumour and Stromal Reprogramming

27-May-2022	Noxopharm announced a research abstract has been published at ASCO 2022 which confirms lead drug candidate, Veyonda’s immunomodulatory properties against nasopharyngeal carcinoma, in combination with the chemotherapy cisplatin.
	Read More here.

24-May-2022	Noxopharm collaborators Hudson Institute of Medical Research confirm the relevance of TLR7 activation in Lupus

27-Apr-2022	Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors
	Read More here.

8-Apr-2022	The reputable Journal of Nuclear Medicine published Noxopharm’s LuPIN trial as its featured article with its results pictured on the cover of the journal’s April edition.
	¹⁷⁷ Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial \| Journal of Nuclear Medicine

21-Jun-2021	Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides

18-Nov-2020	Poster presented at 2020 Annual Meeting of the Clinical Oncology Society of Australia (COSA), “Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma

11-Aug-2020	Publication in international journal (European Urology Oncology) strengthens case for Veyonda as a safe and possibly life-prolonging treatment in late-stage prostate cancer

27-Jul-2020	Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists

12-Nov-2019	LuPIN Data Being Presented To Conference

12-Nov-2019	DARRT-1 Interim Data Presented To Conference

21-Jun-2019	Abstract first published in the Journal of Nuclear Medicine. Interim results of the LuPIN trial. Oral presentation at the Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, June 2019 Anaheim CA

13-Nov-2018	Trial in Progress: NOX66 in combination with Palliative Radiotherapy in patients with CRPC – a Phase 1 safety and dose finding study
	Poster at COSA Annual Meeting Perth November 2018

13-Nov-2018	A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours
	Poster at COSA Annual Meeting Perth November 2018

9-Jul-2018	NOX66 and Palliative Radiotherapy in Patients with Late-Stage Prostate Cancer- A Phase 1b Proof of Concept and Dose Confirmation Study
	Poster presented at Australian and New Zealand Urogenital and Prostate Cancer (ANZUP) Clinical Trials Group Annual Scientific Meeting, Sydney. July 8-10 2018

5-Jun-2018	A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours

6-Mar-2018	NOX66 Plus Low Dose Carboplatin CEP-1 Study Interim Trial Results

20-Nov-2017	NOX66 Plus Carboplatin - Phase 1 Signalling Study

13-Nov-2017	Trial Design: Safety of NOX66 in Combination with Palliative Dose Radiotherapy - A Phase 1 Dose Escalation Study

13-Nov-2017	Idronoxil levels of patients receiving NOX66

13-Nov-2017	ENOX2 levels of patients receiving NOX66

11-Sep-2017	Chemosensitization of Carboplatin by NOX66

Copyright © Noxopharm